Background: CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard chemotherapy regimens in the treatment of small-cell lung cancer (SCLC), with myelosuppression as dose-limiting toxicity. In this trial the impact of prophylactic antibiotics on incidence of febrile leucopenia (FL) during chemotherapy for SCLC was evaluated.
Introduction
CDE is one of the standard chemotherapy regimens in the treatment of SCLC. The dose-limiting toxicity is myelosuppression, with an incidence of febrile neutropenia (FN) or leucopenia (FL) varying at the most commonly used dose from 40% to 53% and 77% at a slightly higher dose [1] [2] [3] . This is a potentially lifethreatening complication of chemotherapy. The addition of the haematopoietic growth factor G-CSF was shown to shorten the duration of neutropenia, resulting in reduction of the incidence of FN, hospitalization and use of intravenous therapeutic antibiotics by approximately 50% [2, 3] . Primarily based on these two pivotal studies, the American Society of Clinical Oncology recommended the use of G-CSF in case the incidence of FN is expected to be more than 40% [4] . However, G-CSF is expensive and requires daily subcutaneous injections.
Prophylactic antibiotics have also been used in combination with chemotherapy to prevent FN, although its role has not been clearly established. Co-trimoxazole has been shown to be effective, also in SCLC [5. 6] , but the emergence of resistance, allergic reactions, and the risk of prolonged neutropenia are important disadvantages [7] . During the last decade, fluoroquinolones have increasingly been used, mostly in patients with hematologic malignancies [8, 9] , showing a significant reduction in the incidence of fever and of bacteremia caused by Gram-negative bacilli. There was, however, no reduction 
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in clinically documented infections or infection-related deaths.
Associated with the use of prophylactic quinolones, the increased use of central venous catheters and more severe oromucositis due to intensified chemotherapy, a shift toward an increased prevalence of gram-positive infections has been observed [10] . Documented bacteremia occurs in approximately 25% to 30% of febrile episodes in neutropenic patients. Gram-positive microorganisms presently cause 60% of these bacteremias. Therefore, a new strategy of prophylaxis against both gram-negative and gram-positive micro-organisms may be more appropriate. The addition of a penicillin, vancomycin or macrolide to a quinolone significantly reduced the occurrence of gram-positive bacteremia [9] .
We report here the results of a double-blinded placebocontrolled randomized trial in patients with SCLC treated with CDE chemotherapy, in which the prophylactic role of the combination ciprofloxacin plus roxithromycin for the prevention of FL was evaluated [10] .
Patients and methods

Patient selection
Patients had to meet the following inclusion criteria: histologically or cytologically proven SCLC. either extensive disease (ED) or limited disease (LD), measurable or evaluable disease, no prior treatment. ECOG performance status (PS) 0-1, 19-69 years, able to undergo treatment and follow-up, white blood cell counts (WBC) 3= 4 xlO 9 /l. platelets (PLT) 3= 100 x 10 9 /!. hemoglobin (Hgb) 3=6.0 mmol/l. creatinine < 140 umol/l and bihrubin < 35 umol/l.
Patients were excluded in case of symptomatic cerebral metastases. evidence of active infection or fever 3= 38.3 °C, uncontrolled hypertension, symptomatic cardiovascular disease within three months prior to enrollment, previous malignancy, except basal or squamous cell skin carcinoma or adequately treated carcinoma in situ of the cervix, any evidence or history of hypersensitivity or other contraindications to the drugs to be investigated in this trial. The investigational protocol was approved by the EORTC Protocol Review Committee and the ethical committee of each institution. Informed consent was obtained from each patient according to the national regulations.
For each patient the pre-treatment information was obtained by the medical history, physical examination, laboratory investigations (blood cell counts, albumin, renal and liver functions), chest X-ray. CTthorax. CT-scan or ultrasound upper abdomen, bronchoscopy and bone marrow biopsy. As soon as a lesion was detected to diagnose ED. no further investigations were indicated.
Study design
This was a phase III trial with a 2 x 2 factorial design ( Figure I ). SCLC patients were randomized to standard-dose or intensified chemotherapy in order to assess the impact of dose-intensification on survival. Results of this part of the study will be reported separately. Secondly, patients were randomized in a double blind fashion to prophylactic antibiotics or to placebo. The primary endpoinl of this comparison was to compare the incidence of FL during the first cycle. FL was defined as a combination of WBC < 1 x IO 9 /1 and an increased temperature (an oral temperature 3= 38.3 °C on one occasion or 3= 38.0 °C on two or more occasions during a 12-hour period (minus 0.5 °C for axillary temperature). Secondary endpoints were impact of prophylactic antibiotics on the incidence of FL in the second and subsequent cycles, on the number of days with fever, on the number of days from start of chemotherapy until the onset of fever in the first cycle, on the number of documented gram-positive and gram-negative infections, on the number of days of intravenous therapeutic antibiotics and on the number of days of hospitalization. Over a period of 3V4 years. 161 eligible patients were randomized from 13 European centers At that point, the antibiotic-placebo randomization was prematurely stopped following the recommendation of an independent data-monitoring committee. We report here the final results of the antibiotic part of this trial.
Data-management and monitoring were earned out by the EORTC. All patients were asked to keep a diary for registration of orally or axillary measured temperature, every morning. In case of increased temperature (see above), patients were instructed to contact the hospital and be checked for blood cell counts and cultures of serum samples and/or a suspected source, with susceptibility tests against both ciprofloxacin and roxithromycin, as well as the routine antibiogram In case of FL. ciprofloxacin-roxithromycin (verum or placebo) was interrupted and replaced by intravenous antibiotics, that is a combination of aminoglycosides and a second or third generation cephalosporine. Complete blood cell counts were to be performed daily until resolution of FL. Intravenous antibiotic treatment was discontinued when all signs of infection and/or fever were resolved, at the discretion of the treating physician. Febrile episodes were classified as microbiologically documented infections, when a micro-organism was isolated from the site of infection or serum, clinically documented infections, when there was clinical or radiological evidence of infection: and fevers of unknown origin, when both microbiological and clinical evidence of infection were absent. In subsequent cycles the prophylaxis (verum or placebo) were to be restarted in a double blind fashion.
Chemotherapy regimen
Standard CDE chemotherapy consisted of cyclophosphamide 1000 mg/m 2 on day 1, doxorubicin 45 mg/m 2 on day 1 and etoposide 100 mg/m" on days 1-3 intraveneously, every three weeks for five cycles. Intensified CDE chemotherapy consisted of cyclophosphamide 1250 mg/m 2 on day I, doxorubicin 55 mg/m 2 on day I and etoposide I25 mg/m 2 on days 1-3 intraveneously, every two weeks for four cycles [II] . The total dose of chemotherapy was the same in both arms, but the planned dose-intensity (Dl) was double in the intensified arm by increasing dose size and reducing treatment intervals. Chemotherapy was prematurely discontinued in case of treatment failure, unacceptable toxicity or patient refusal. Dose adjustments in chemotherapy were based on day I blood count levels and on WBC and/or PLT nadir. Blood counts were measured on day 8, 12 and 15 during intensified CDE and on day 8, 12, 15, 19 and 22 during standard CDE.
G-CSF
In the intensified arm. G-CSF (filgrastim) was added on days 4-13 at a dose of 300 ug/day if body weight was ^ 75 kg and at a dose of 5 ug/kg/day if body weight was > 75 kg. G-CSF was not added in order to reduce febrile complications, but to facilitate dose-intensification.
Antibiotic prophylaxis
The antibiotic prophylaxis consisted of a combination of ciprofloxacin and roxithromycin. The antibiotics were given as verum. i.e.. active compounds, or as placebo (antibiotics-placebos were provided free by the sponsor). The placebo matched the active drugs in appearance, taste and weight. The active compounds and the placebo were supplied in treatment packs which represented the complete antibiotic drug regimen per patient, to be taken during the chemotherapy cycles, i e , ciprofloxacin 750 mg b.i.d. per os and roxithromycin 150 mg b.i.d. per os, days 4-13. Counts were to be made of dose units remaining at the end of therapy, so that an indication of compliance could be obtained. A sealed envelope for each box specifying the antibiotic-placebo schedule was lodged by the pharmacist of each hospital This envelope was only to be opened in case of an emergency. At randomization the EORTC Data Center assigned a unique treatment pack to the patient.
Radiation therapy
Local sequential radiation therapy in case of CR in LD patients was allowed, with the remark that each institute had to follow one strategy. Prophylactic cranial irradiation at the end of chemotherapy in case of CR in LD patients was also allowed according to institutional policy, and participants were advised to take part in the EORTC study 08921.
to close this part of the study was written and approved by the EORTC Protocol Review Committee At the time of analysis 161 eligible patients had been entered. Given a sample size of 161 patients we should have been able to demonstrate the above-assumed reduction with a power of approximately 80%. using a one-sided significance level of 5% (Cochran-Mantel-Haenszel lest). A one-sided significance level was chosen as it was not expected that giving prophylactic antibiotics would show an increase in the risk of FL. The interim analysis covered all aspects of the trial. Randomization was done using the minimization technique stratifying patients according to their institution, age (>60 vs. ^60 years) and stage of disease (LD vs. ED) [12] . The trial was analyzed as a 2x2 factorial design. Thus, for all statistical comparisons the effect of prophylactic antibiotics was analyzed after stratification for the regimen (standard or intensified). The number of days with FL, the number of days of intravenous therapeutic antibiotics, and the number of days of hospitalization were compared between the two treatment groups using a stratified WilcoxonMann-Whitney test The analysis was performed on all eligible patients according to the treatment arm they were allocated to by randomization independently of the treatment they actually received. For analysis of toxicity data and description of treatment compliance, the analysis was based on the treatment the patient actually received. For analysis of all pre-specificd protocol endpoints relating to the antibiotics question a one-sided test was used. For the comparison of the number of toxic deaths a two-sided test was chosen, as it was not possible to hypothesize a priori in which direction the difierence would be. An analysis of prognostic factors was performed to investigate which baseline factors were predictive for the occurrence of FL The logistic regression model was used with a two-sided test at the 5% significance level to test the predictive value of each variable [13] . A step-down variable selection procedure was used for building the mullivanate model. The importance of a prognostic factor was expressed by the percentage of patients presenting with FL. odds ratio (OR: the odds of having FL vs. no FL in patients with that specific value as compared to the odds in the reference category), its 95% confidence interval (95% CI) and the P-value of the chi-square statistic.
Results
A total of 163 patients were randomized to receive placebo (/; = 80) or verum antibiotics (n =83). Two patients, one in each arm, were considered ineligible: one due to an incorrect diagnosis and one due to double registration by error. The characteristics of eligible patients are shown in Table 1 . Both arms were well-balanced. The majority of patients had LD. All patients started treatment within eight days after randomization.
Statistical considerations
The trial was designed as a 2 x 2 factorial design. It was calculated that a total of 192 deaths would permit the detection of an increase in median survival from 12 months in the standard CDE arm to 18 months in the intensified CDE arm at a two-sided significance level of 5% and with a power of 80%. A total of 240 (60 in each strata) needed to be randomized to observe this number of events. Computer simulations showed that given a sample size of 240 patients, we should be able to demonstrate a 20% absolute decrease in the risk of FL when patients are treated with the prophylactic antibiotics with a statistical power of approximately 90%. using a two-sided significance level of 5%.
After inclusion of 163 patients, the EORTC-LCG group decided to perform an unplanned interim analysis because of concerns with respect to the incidence of FL. The results were submitted to an Independent Data Monitoring Committee (1DMC). They recommended to prematurely stop the antibiotic-placebo part of the protocol on ethical grounds. Following this recommendation a protocol amendment
Delivered chemotherapy
Nearly 80% of patients in both arms completed the planned number of cycles. The median delivered DI for cycles actually delivered was 96.7% of planned (range 53.1%-1O2.8%) for the placebo arm and 97.0% (range 44.3%-165.5%) for the antibiotic arm.
Delivered antibiotic prophylaxis (verum or placebo)
Seventy-one percent of patients in the antibiotics arm compared to 54% of patients in the placebo arm received the planned prophylactic medication for chemotherapy cycles given ( Table 2) . One of the main causes of this difference was a higher incidence of FL in the placebo 
arm. In cycles with FL the prophylaxis was temporarily interrupted and replaced by intravenous antibiotics.
Toxicity
The worst overall toxicity during all cycles is demonstrated in Table 3 . Myelosuppression was not significantly different between the two arms: the median WBC nadir over all cycles was 0. (5) 2 (5) 3 (7) 4 (10) 0 (0) 3 (7) 1 (2) 0(0) (13) 10 (24) 31 (76) 8 ( 4 (10) 7» (18) 10 (24) 31 (76)
bocyte nadirs were: 52 X 10 9 /l (range 0.0-280) in the Table 4 Incidence and duration of febrile lcucopenia(FL).
placebo arm versus 50 x 10 9 /l (range 1-273) in the antibiotics arm. For Hgb: 5.2 mmol/1 (range 1.8-8.9) in the placebo arm vs. 5.1 mmol/1 (range 2.9-9.2) in the antibiotics arm. There was no difference in number of transfusions. Myelosuppression was more severe in patients treated with intensified chemotherapy compared to those treated with standard chemotherapy (Table 3a) .
Non-hematologic toxicities were in general mild. More patients in the antibiotics arm suffered from nausea grade 2-3, and this was the reason for discontinuing the antibiotic prophylaxis in two patients (grade 2: not presented in Table 3 ). Stomatitis, mucositis and diarrheâ grade 2 occurred less frequently in the antibiotics arm, probably reflecting the efficacy of antibiotics in preventing mucosal infections.
Death due to infection occurred only in the placebo arm (see next section). Two patients in the antibiotic arm died from cardiac disease. One patient had a cardiac failure after the first day of chemotherapy prior to starting antibiotics, most probably related to acute doxorubicin toxicity. The second patient died suddenly at home, most probably due to a cardiac infarction five days after the second chemotherapy cycle. Both patients had a history of cardiovascular impairment. One patient in the placebo arm had a fatal hemoptysis. Although grade 4 leucopenia and thrombocytopenia were observed on date of death, hemorrhage was considered to be caused by a tumor erosion into one of the lung arteries.
Febrile leucopenia and sequelae of fever
Prophylactic ciprofloxacin and roxithromycin significantly reduced the overall incidence of FL by nearly 50% (Table 4, Figure 2 ). The highest incidence of FL was seen among the group of patients who received intensified chemotherapy; this group seems to benefit the most from prophylactic antibiotics.
Most patients suffered only once from a period of FL. It is of note that in the placebo-intensified group 7 (17%) patients had two to four episodes of FL.
In total 48 episodes of FL occurred in the placebo arm (15% of 320 chemotherapy cycles) vs. 23 in the antibiotics arm (7% of 335 cycles). The incidence of FL was the highest during cycle 1 and decreased thereafter, in both arms.
The duration of FL was significantly shorter for the antibiotics arm (P = 0.007; 1-sided test), however, based on patients who actually developed FL, the duration of FL was not different (median of two vs. three days).
The time from start of chemotherapy to the onset of fever in the first cycle was not different between both arms: median in placebo was nine days (range 0-15) and median in antibiotics was nine days (range 2-17) with 1-sided P-value of 0.459.
The incidence of fever was higher in the placebo arm ( 1-11 ) in the placebo arm and three (range 1-9) in the antibiotics arm arm: 6% of all placebo patients vs. 0% of verum patients (P = 0.022; 2-sided) representing 10% of placebo patients who developed fever. Infectious deaths occurred with both intensified and standard chemotherapy and this was equally effectively prevented by the use of prophylactic antibiotics. The majority of deaths due to infection occurred in the first two cycles of treatment: two after the first, two after the second and one after the fourth cycle. All five patients had developed a pneumonia, and three of them had a positive blood or bronchoalveolar lavage culture (Ps. aeruginosa, H. influenzae. S. pneumonia), which was shown to be sensitive to one of the two antibiotic agents used in the other, antibiotics, arm. No cultures were made from the other two patients.
There were 38 clinically documented infections in the placebo arm versus 15 in the antibiotics arm, with mainly less respiratory and urinary infections in the antibiotics arm. There was a reduction in the number of microbiologically documented infections: 32 in the placebo arm vs. 9 in the verum arm, i.e., 10 vs. 5 in the standard and 22 vs. 4 in the intensified group of patients. The largest gain was observed for gram-negative infections in the group of patients who received intensified chemotherapy. Table 6 shows the number of days of hospitalization and of intravenous antibiotics. There was a significant difference in number of days of hospitalization due to FL (P = 0.013; 1-sided) and use of intravenous antibiotics (P = 0.013; 1-sided), in favour of the antibiotics arm. However, the overall number of days of hospitalization was not reduced (P-0.05; 1-sided). Again, the largest differences were observed in the group of patients who received intensified chemotherapy.
-
Baseline predictive factors for the occurrence of febrile leucopenia
Factors included in the logistic regression were age (< 60 vs. ^ 60 years), weight loss (^ 5% vs. > 5%), PS (0 vs. 1), disease status (LD vs. ED), antibiotics (placebo vs. verum), chemotherapy regimen (standard vs. intensified) and a term for interaction between chemotherapy and antibiotics treatment. The step-down variable selection procedure removed from this model the interaction term (P = 0.130), PS (/» = 0.063), weight loss {P = 0.072) and the chemotherapy regimen (P -0.07). Table 7 presents the final multivariate model. This model indicated that having ED (P-0.007) and being older than 60 (P = 0.0425) are predictive factors for FL as well as being randomized to the placebo arm (P = 0.017). The fact that the interaction between chemotherapy and antibiotics treatment has not been found to be significant was expected as we do not have enough power to test this interaction.
Discussion
This placebo-controlled randomized trial demonstrates that prophylactic ciprofloxacin and roxithromycin during CDE chemotherapy in patients with SCLC can reduce the incidence of FL, the number of documented infections, hospitalization due to FL and use of therapeutic antibiotics by approximately 50%, with reduced number of infectious deaths.
The present study was designed to address two SCLC treatment issues at the same time: 1) the impact of chemotherapy dose intensification on survival, and 2) the role of antibiotic prophylaxis in the prevention of FL. The antibiotic-placebo randomization was halted, far before its planned accrual of 240 patients, as results of interim-analysis showed excessive toxicity in the placebo arm. It should be emphasized that all analyses were made under strict double-blinded conditions, and that the results were evaluated by an IDMC before the Placebo Antibiotics Stratified (n = 79) (n = 82) /'-value decision to terminate this part of the study was made. With the number of randomized patients there was enough statistical power to analyse the antibiotics endpoint. The trial was continued for the main endpoint of survival as a two-arm study (standard vs intensified dose) with all the remaining patients receiving prophylactic antibiotics as suggested by the IDMC. The results concerning the impact of chemotherapy DI on survival will be reported separately. The incidence of FL was higher in the intensified chemotherapy arm when compared to the standard chemotherapy arm. Moreover, the protective effect of antibiotics was especially seen in the intensified arm, with a larger reduction in incidence of FL and documented infections compared to the standard arm. Infectious deaths occurred with both intensified and standard chemotherapy and this was equally effectively prevented by the antibiotic prophylaxis. The outcome seems to indicate an interaction between the efficacy of prophylaxis and the DI of chemotherapy, which was not anticipated beforehand. However, we have no power to test this possible interaction. The data presented in the tables are stratified by chemotherapy DI.
In this patient population the presence of ED and elderly age were predictive for FL. For example, the overall incidence of FL was 19 of 35 (54%) in the placebo arm and 11 of 30 (37%) in the antibiotics arm in of antibiotic prophylaxis in neutropenic cancer patients [8, 9] . Engels et al. evaluated 18 trials which included 1408 subjects [8] . Compared with no prophylaxis, quinolones significantly reduced the incidence of gram-negative bacterial infections (relative risk 0.21), total infections (0.54) and episode with fevers (0.85) in patients who had a mean duration of neutropenia ranging from 7 to 32 days. Quinolone prophylaxis alone did not reduce clinically documented infections or infection-related deaths. A combination of a quinolone plus prophylaxis against gram-positive bacilli (penicillin, vancomycin, or macrolides) compared to a quinolone alone significantly reduced gram-positive bacteremia (relative risk 0.46) without affecting the incidence of fever-related morbidity or mortality [9] . In other words, although both antibiotics were demonstrated to be effective in reducing microbiologically documented infections, each of them used separately demonstrated only a small benefit, if any, when looking at fever-related morbidity and mortality with conflicting data concerning the subsequent effect on antibiotic usage, hospitalization and cost-effectiveness [14] [15] [16] . Consequently, the use of antibiotic prophylaxis has not gained widespread acceptance, certainly not for patients with only modest leucopenia, i.e., not for patients with solid tumors treated with standard dose chemotherapy. To our knowledge, this is the first trial in which double antibiotic prophylaxis was compared to placebo, in contrast to the above-mentioned trials in which double antibiotics prophylaxis was always compared to one other antibiotic agent or single antibiotic prophylaxis compared to placebo. The sum of protective effects of both drugs in our trial may explain the significant reduction in fever-related morbidity and mortality.
Whether the reduced need for intravenous antibiotics and less hospitalizations will outweight the costs of prophylactic antibiotics at this infection rate, has been a subject of separate cost-effectiveness analysis [17] .
Although this was not an end point of this study, an important observation was the absence of death due to infection in the antibiotics arm compared with 6% in the placebo arm, for both intensified and standard chemotherapy. A reduction in death due to infection rate was in general not demonstrated by the addition of a single antibiotic prophylaxis agent, nor in the haematopoietic growth factor trials [2, 3, 8, 9] . Six percent deaths due to infection seems rather high for the degree of leucopenia seen, but this figure is in concordance with the literature [3] . All five patients had developed a pneumonia, and bacteremic pneumonia in neutropenic cancer patients is known to be associated with a poor outcome [18] . It must be emphasized that this is a multicenter trial, and it is well known that mortality in such large studies is often higher in comparison to single institution trials. Furthermore, this is a relative elderly patient population with frequently additional smoking-associated morbidity like emphysema, besides increased risk of postobstructive pneumonia due to the tumor. A British trial in 610 SCLC patients observed 71 (12%) deaths in the first three weeks after start of chemotherapy, corresponding to the onset of neutropenia and related to a worse PS [19] .
The antibiotics were protective through all cycles with a consistent 50% relative difference in occurrence of FL between both arms. The incidence of FL declined over the subsequent cycles, which cannot be explained by chemotherapy dose reductions with less myelosupression, since the nadir WBC counts were quite consistent during the whole treatment period (non presented data). The declining incidence of FL and infectious mortality may reflect patient selection during treatment and tumor response in this chemo-sensitive disease with less risk for postobstructive pneumonia during later cycles. One may question the value of prophylactic antibiotics during later cycles, as the absolute difference between the two arms diminishes during cycles 2-5.
Grade 4 leucopenia was seen in 23% of delivered chemotherapy cycles in the placebo arm, with FL occurring in 49% of these leucopenic cycles. In a retrospective analysis of patients treated with standard-dose chemotherapy for solid tumors, it was seen that leucopenia occurred in 7% of cycles [20] . In case of leucopenia the incidence of FL without prophylaxis was 34% [22] . Both latter figures are much lower compared to our observation in the placebo arm. It may be concluded that the risk for infection and the efficacy of antibiotic prophylaxis in our study is partly related to the type of tumor (lung cancer with risk for obstructive pneumonia), in addition to the degree of chemotherapy-induced leucopenia. The conclusion that the efficacy of antibiotic prophylaxis is related to chemotherapy-induced leucopenia and not only to tumor-related infections is also supported by the observation of a significant difference between the incidence of FL (48 episodes in the placebo arm vs. 23 in the antibiotics arm), but no difference between the incidence of febrile episodes without leucopenia (30 episodes in placebo arm vs. 29 episodes in antibiotic arm).
A major criticism of many previous antibiotic trials is that a reduction in microbiologically documented infections frequently results in a shift toward more clinically documented infections and episodes of fever of unknown origin, of which the microbiological source is masked by the prophylactic antibiotic. This was not the case in our trial, with overall less febrile episodes. As could be expected by the tumor location and by the smoking behavior of these patients, the majority of infections were seen in the respiratory tract. In this respect, it is important to realize that ciprofloxacin and roxithromycin achieve high tissue levels when administered orally [21, 22] , with no antagonistic interactions [23] .
The design and outcome of our study is quite similar to the G-CSF studies in SCLC [2, 3] . The guidelines of the American Society of Clinical Oncology concerning the use of prophylactic G-CSF is primarily based on these two pivotal studies [4] . The CDE regimen in the G-CSF studies was higher dosed than our standard CDE regimen, but had a lower DI than our intensified, G-CSF-supported, CDE regimen [2, 3] . In their placebo non-G-CSFarms, however, the degree of myelosuppression was more severe, and this explains partly the higher incidence of FN in the placebo arms of these studies (77% and 58%), besides the use of a more stringent definition of FN (i.e., a temperature >38.2°C and neutrophils (not WBC counts) < 1 x 10 9 /l) and differences in patient characteristics, with more patients having an ED and PS 2. As stated above, one may speculate that especially these patients, with an increased risk for FN due to high-dose CDE and more often ED and worse PS [2, 3] , were able to benefit from G-CSF prophylaxis.
With the outcome of our trial, it can be hypothesized that antibiotics can be an alternative to G-CSF for the prevention of FL. Prophylactic antibiotics are also less expensive than G-CSF and subcutaneous injections can be avoided. Some support for the hypothesis that G-CSF and antibiotics give similar results can be found in the literature. In a retrospective analysis 62 patients with ovarian cancer receiving a taxol-based chemotherapy regimen were prophylactically treated with either ciprofloxacin or G-CSF, while a third group received no prophylaxis. There were two episodes of FN in the antibiotic group and three in the G-CSF group, compared with 15 in the observation group [24] . Recently, a prospective comparison between G-CSF vs. ciprofloxacin and amphothericin B in patients with breast cancer treated with high-dose chemotherapy has been reported [25] . The incidence of FL was comparable, while the treatment with G-CSF was six times more expensive. In another prospective trial, 59 patients were randomized to either G-CSF alone or G-CSF plus a quinolone [26] . With a median duration of WHO grade 4 leucopenia of four days, FL occurred three times as often in the G-CSF only arm compared to the experimental arm. As these trials were either retrospective or included too few patients, firm conclusions cannot be drawn. Well-designed prospective trials should be launched to investigate which type of prophylaxis (antibiotics or G-CSF or both) represents the optimal strategy for specific groups of patients based on their risk of developing FL.
In conclusion, this study has demonstrated that prophylactic ciprofloxacin and roxithromycin are well tolerated and effective in reducing FL and infections in SCLC patients receiving CDE chemotherapy. The protective effect of antibiotics was especially seen in patients who were treated with intensified chemotherapy. In this patient population with an excellent PS, patients with an ED and elderly age had an increased risk of FL.
Similarly to G-CSF, ciprofloxacin-roxithromycin antibiotic prophylaxis can be recommended to prevent infectious complications in patients with an increased risk for FL during chemotherapy.
